Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NK Cell Frontie | Explore Nkarta's innovative approach to cell therapy, leveraging natural killer cells for potential breakthroughs in cancer and autoimmune disease treatment |
Financial Fortitude | With $427 million in cash, Nkarta is well-positioned to fund operations into late 2027, providing ample runway for clinical advancements |
NKX019: Game Changer? | Delve into the potential of Nkarta's lead product, NKX019, and its advantages in safety, administration, and re-dosing capabilities |
Market Valuation | Analyst price targets range from $11 to $20 per share, with a consensus "Strong Buy" recommendation, suggesting significant upside potential |
Metrics to compare | NKTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −2.6x | −0.5x | |
PEG Ratio | −0.04 | −0.05 | 0.00 | |
Price/Book | 0.4x | 0.9x | 2.6x | |
Price / LTM Sales | - | 7.0x | 3.3x | |
Upside (Analyst Target) | - | 318.4% | 43.5% | |
Fair Value Upside | Unlock | 25.9% | 6.8% | Unlock |